Table 3.
Simulated patient population and clinical characteristics.
| Patient characteristics | All patients (n = 158) No. (%) | GP (n = 71) No. (%) | TPF (n = 87) No. (%) | P |
|---|---|---|---|---|
| Age | 0.297 | |||
| Median, range | 46 (19−71) | 48 (19−68) | 45 (22−71) | |
| <46 | 74 (46.8) | 30 (42.3) | 44 (50.6) | |
| ≥46 | 84 (53.2) | 41 (57.7) | 43 (49.4) | |
| Gender | 0.420 | |||
| Male | 106 (67.1) | 50 (70.4) | 56 (64.4) | |
| Female | 52 (32.9) | 21 (29.6) | 31 (35.6) | |
| Karnofsky Performance Status scores | 0.336 | |||
| 90−100 | 139 (88.0) | 61 (85.9) | 79 (90.8) | |
| 70−80 | 19 (12.0) | 10 (14.1) | 8 (9.2) | |
| Tumor stage | 0.843 | |||
| T1−2 | 48 (30.4) | 21 (29.6) | 27 (31.0) | |
| T3−4 | 110 (69.6) | 50 (70.4) | 60 (69.0) | |
| Node stage | 0.194 | |||
| N1 | 42 (26.6) | 15 (21.1) | 27 (31.0) | |
| N2 | 79 (50.0) | 41 (57.7) | 38 (43.7) | |
| N3 | 37 (23.4) | 15 (21.1) | 22 (25.3) | |
| Disease stage | 0.810 | |||
| III | 55 (34.8) | 24 (33.8) | 31 (35.6) | |
| IVA | 103 (65.2%) | 47 (66.2) | 56 (64.4) |
GP, gemcitabine plus cisplatin; TFP, docetaxel, fluorouracil plus cisplatin.